Abstract
The dopamine agonist cabergoline has been used to treat prolactinomas, Parkinson's disease, Cushing's disease, and sexual dysfunction. However, its clinical use was severely curtailed when it was found that patients taking cabergoline had an increased risk of developing cardiac-valve regurgitation. This potentially life-threatening condition has been associated with drugs, such as cabergoline, that are 5-HT2B receptor agonists. We prepared analogs of cabergoline and have identified several that have limited or no agonism at the 5-HT2B receptor.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 254-258 |
| Number of pages | 5 |
| Journal | ACS Medicinal Chemistry Letters |
| Volume | 4 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 14 2013 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 5-HT2B
- Cabergoline
- dopamine agonist
- ergot alkaloid
- sexual dysfunction
Fingerprint
Dive into the research topics of 'Synthesis of novel analogs of cabergoline: Improving cardiovascular safety by removing 5-HT2B receptor agonism'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS